Researchers at the National Cancer Institute (NCI) The National Institutes of Health (NIH) has developed an artificial intelligence tool that uses individual tumor cells to predict whether a patient will respond to cancer drugs, according to research published in Nature Cancer.
Traditional approaches to drug-patient matching focus on bulk sequencing of tumor DNA and RNA. The new AI approach, named PERCEPTION, leverages single-cell RNA sequencing to provide better resolution data to fine-tune predicted drug responses.
This new approach has shown promise in two clinical trials for myeloma and breast cancer.
This study quantifies the effectiveness of drug combinations in clinical trials to optimally rank them according to the response of individual tumor cells to treatment, allowing researchers to determine which treatment is most effective for a given patient. Allowed to decide the law.
bigger trends
The NIH announced in October: A study funded by the company found that a tablet application could be used for early screening for autism. This study aims to provide patients and parents with the necessary support by accurately identifying patients at an early stage.
In February, the NIH has launched the Cancer Screening Research Network to evaluate the latest technology in cancer screening, with the aim of detecting cancer early. The network plans to begin a pilot study this year to determine the effectiveness of using multiple cancer detection in clinical trials.
On April 11, the NIH We published a study in Nature that adapted an AI program to predict signs of PTSD after childbirth. This tool examines the statements of patients who have given birth and is used to identify patients at risk for this disease.
Artificial intelligence is widely used in life sciences for drug discovery.
based in israel AION Labs is an AI-enabled drug discovery company founded through a government tender. The organization is comprised of global pharmaceutical and technology companies AstraZeneca, Merck, Pfizer and Teva, venture capital firm Israel Biotech Fund, strategic partner Amazon Web Services and German independent research institute BioMedX. Established in partnership with.
AION has launched numerous AI-powered drug discovery companies, including: OMEC.AI, DenovaAI, CombineAble.AI, TenAces.
